SCHEMBL4477239

SCHEMBL4477239

Nc1nc(NCC2CCCCC2)nc(C[C@H]2CC[C@H](N)CC2)c1[N+](=O)[O-]

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
NPC1 O15118 1/20 0.43
MITF O75030 1/20 0.43
RAB9A P51151 1/20 0.43
CCNA2 P20248 1/20 0.41
CDK2 P24941 1/20 0.41
CCNA1 P78396 1/20 0.41
KMT2A Q03164 5/20 0.41
MEN1 O00255 4/20 0.41
MAPK1 P28482 1/20 0.39
USP2 O75604 1/20 0.39
POLB P06746 1/20 0.39
GSK3A P49840 3/20 0.38
GSK3B P49841 3/20 0.38
MAPT P10636 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
BLM P54132 1/20 0.38
CDK5 Q00535 1/20 0.38
ATM Q13315 1/20 0.38
CDK5R1 Q15078 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3815629 0.91 NPC1 (0.46) ALDH1A1NPC1MITFRAB9ACCNA2
SCHEMBL4481149 0.81 KMT2A (0.40) ALDH1A1NPC1MITFRAB9AKMT2A
SCHEMBL4475566 0.81 MAPT (0.60) ALDH1A1KMT2AMAPK1POLBMAPT
SCHEMBL4473465 0.80 MAPT (0.47) ALDH1A1KMT2AMEN1MAPK1POLB
SCHEMBL4483366 0.79 ALDH1A1 (0.37) ALDH1A1NPC1MITFRAB9AKMT2A
SCHEMBL4481691 0.79 KMT2A (0.39) ALDH1A1NPC1MITFRAB9AKMT2A
SCHEMBL4491551 0.79 CYP1A2 (0.43) ALDH1A1NPC1MITFRAB9AKMT2A
SCHEMBL4479093 0.79 PRKCQ (0.46) ALDH1A1NPC1KMT2AMEN1MAPK1
SCHEMBL4479341 0.78 KMT2A (0.57) KMT2AMAPK1POLBMAPTCDK5
SCHEMBL4476189 0.77 MAPT (0.36) ALDH1A1NPC1MITFRAB9ACCNA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7601714-B2 Pyrimidine derivatives useful as inhibitors of PKC-theta BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2009-10-13 US disclosed
US-20080287410-A1 PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA BARBOSA ANTONIO J M 2008-11-20 US disclosed
EP-1765791-A1 PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2007-03-28 EP disclosed
WO-2006014482-A1 PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-02-09 WO disclosed
US-20060025433-A1 Pyrimidine derivatives useful as inhibitors of PKC-theta BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287410-A1 PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA PRKCZ, PRKCQ, PRKCH ALDH1A1 4365/4885NPC1 4117/4885MITF 2257/4885
US-20060025433-A1 Pyrimidine derivatives useful as inhibitors of PKC-theta PRKCZ, PRKCQ, PRKCH ALDH1A1 4365/4885NPC1 4117/4885MITF 2257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.